Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.
Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. Karantanos T, et al. Among authors: dalton wb. Sci Adv. 2022 Feb 18;8(7):eabl8952. doi: 10.1126/sciadv.abl8952. Epub 2022 Feb 18. Sci Adv. 2022. PMID: 35179961 Free PMC article.
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, DeZern AE. Hambley BC, et al. Among authors: dalton wb. Leuk Res. 2019 Aug;83:106174. doi: 10.1016/j.leukres.2019.106174. Epub 2019 Jun 21. Leuk Res. 2019. PMID: 31255938 Clinical Trial. No abstract available.
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, DeZern AE, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Lauring J, Park BH. Dalton WB, et al. J Clin Invest. 2019 Aug 8;129(11):4708-4723. doi: 10.1172/JCI125022. J Clin Invest. 2019. PMID: 31393856 Free PMC article.
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Webster JA, Luznik L, Tsai HL, Imus PH, DeZern AE, Pratz KW, Levis MJ, Gojo I, Showel MM, Prince G, Bolaños-Meade J, Gondek LP, Ghiaur G, Dalton WB, Jain T, Fuchs EJ, Gladstone DE, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Jones RJ, Smith BD. Webster JA, et al. Among authors: dalton wb. Blood Adv. 2020 Oct 27;4(20):5078-5088. doi: 10.1182/bloodadvances.2020002945. Blood Adv. 2020. PMID: 33080006 Free PMC article.
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Ambinder A, Smith M, Tsai HL, Varadhan R, DeZern A, Dalton W, Gocke C, Webster J, Gondek L, Gojo I, Ali SA, Huff CA, Swinnen L, Wagner-Johnston N, Showel M, Prince G, Borrello I, Bolaños-Meade J, Luznik L, Jain T, Imus P, Fuchs E, Ambinder R, Gladstone DE, Levis M, Jones R, Ghiaur G, Smith BD. Ambinder A, et al. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):260-269. doi: 10.1016/j.clml.2021.09.022. Epub 2021 Oct 9. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34750086 Free PMC article.
How low risk are low risk myelodysplastic syndromes?
DeZern AE, Dalton WB. DeZern AE, et al. Among authors: dalton wb. Expert Rev Hematol. 2022 Jan;15(1):15-24. doi: 10.1080/17474086.2022.2029698. Epub 2022 Jan 24. Expert Rev Hematol. 2022. PMID: 35041576 Review.
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.
Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Jain T, et al. Among authors: dalton wb. Transplant Cell Ther. 2022 May;28(5):259.e1-259.e11. doi: 10.1016/j.jtct.2022.02.004. Epub 2022 Feb 11. Transplant Cell Ther. 2022. PMID: 35158092 Free PMC article.
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Karantanos T, et al. Among authors: dalton wb. Leuk Lymphoma. 2022 Aug;63(8):1942-1948. doi: 10.1080/10428194.2022.2057488. Epub 2022 Apr 4. Leuk Lymphoma. 2022. PMID: 35379077 Free PMC article.
43 results